# US 2021/0277040 A1 · Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277040 A1
- Document ID: US20210277040A1
- Status: Published application
- Kind: A1
- Application number: 17/330,822
- Filed: 2021-05-26
- Published: 2021-09-09
- Earliest claimed: 2017-05-05
- Assignees: Bold Therapeutics, Inc.
- Applicants: Bold Therapeutics, Inc.
- Inventors: Tomas Vojkovsky; Kevin Sill; Adam Carie
- Web page: https://patentgrep.com/patent/US20210277040A1

## CPC

- C07F 15/0053: {without a metal-carbon linkage}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/243: Platinum; Compounds thereof
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/02: specific for leukemia
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the preparation of compositions comprising sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)]. Synthesis and formulation preparation is detailed. Impurity profiles are also discussed. Compositions herein are useful for anti-cancer applications.

## Claims

### Claim 1

A compound of Formula I-a:

### Claim 2

A composition comprising sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)], sodium citrate, citric acid, and mannitol.

### Claim 3 (depends on 2)

The composition of claim 2, further comprising mer,trans-[RIIICl3(Hind)2(H2O)].

### Claim 4 (depends on 3)

The composition of claim 3, further comprising a cesium salt.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] is amorphous.

### Claim 6 (depends on 5)

The composition of claim 5, wherein:
mer,trans-[RIIICl3(Hind)2(H2O)] is between about 0.01 and about 0.4 weight percent of the composition,
and cesium is between about 0.00001 and about 0.01 weight percent of the composition.

### Claim 7 (depends on 6)

The composition of claim 6, wherein:
mer,trans-[RIIICl3(Hind)2(H2O)] is between about 0.01 and about 0.3 weight percent of the composition,
and cesium is between about 0.00001 and about 0.01 weight percent of the composition.

### Claim 8 (depends on 7)

The composition of claim 7, wherein:
mer,trans-[RIIICl3(Hind)2(H2O)] is between about 0.01 and about 0.2 weight percent of the composition,
and cesium is between about 0.00001 and about 0.01 weight percent of the composition.

### Claim 9 (depends on 4)

The composition of claim 4, wherein the composition is a lyophilized powder.

### Claim 10 (depends on 4)

The composition of claim 4, wherein:
sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] is about 40 to about 60 weight percent of the composition,
mannitol is about 40 to about 60 weight percent of the composition,
citric acid is about 0.01 to about 0.5 weight percent of the composition,
and sodium citrate is about 0.001 to about 0.25 weight percentage of the composition.

### Claim 11 (depends on 4)

The composition of claim 4, further comprising RuIIICl3(Hind)2(H2O), RuIIICl3(Hind)2(CH3CN), and RuIIICl3(Hind)(HN═C(Me)ind).

### Claim 12 (depends on 11)

The composition of claim 11, wherein:
the RuIIICl3(Hind)2(H2O) is not more than about 0.5 weight percentage of the composition,
the RuIIICl3(Hind)2(CH3CN) is not more than about 1.25 weight percentage of the composition,
the RuIIICl3(Hind)(HN═C(Me)ind) is not more than about 1.0 weight percentage of the composition.

### Claim 13 (depends on 2)

A method for treating cancer in a patient in need thereof comprising administering IT-139, or a pharmaceutically acceptable composition thereof, according to claim 2.
